Abstract 5746
Background
The next-generation sequencing (NGS) technology has increased the number of genes and types of genomic alterations detectable by a high-throughput assay and has become an essential part of clinical decision-making. We aimed to verify the analytical specifications of TruSight™ Tumor 170 (TST170, Illumina Inc.) panel for detecting 5% variant allele frequency (VAF) and reliable amplifications (copy number variants, CNVs) for ensuring high quality of sequencing results.
Methods
We use well-characterized human cancer cell lines mixtures with known specific gene mutations to evaluate the specifications given by TST170 and defined thresholds for each type of genomic alterations intended to detect. We performed the following mixing studies by using the lung adenocarcinoma cell lines H1975 and H1299 to acquired proportions: 100%, 33%, 10% and 2% H1975. H1975 harbors EGFR p.Thr790Met (c.2369C>T), p.Leu858Arg (c.2573T>G), TP53 p.Arg273His (c.818G>A), CDKN2A p.Glu69Ter (c.205G>T) and PIK3CA p.Gly118Asp (c.353G>A). H1299 harbors an EGFR, CDKN2A, PIK3CA wild type and a homozygous partial deletion of the TP53 gene. We extracted DNA and performed NGS TST170 analysis with each diluted sample.
Results
When we calculated the correlation between the expected and observed VAFs by linear regression analysis, the coefficient of determination was 0.99 in hotspot NSCLC genes. This result further supports the reliability of this system for variant identification. Mutations with a low VAF (<5%) were identified in half of the mutations and all mutations with >5% VAF were detected without exception. In the CNV analysis, the number of copies seen in the undiluted cell line (100% H1975) were found in all 33% dilution cases, in one third of the 10% dilution cases and in no case in the 2% dilution, independently of undiluted cell line fold changes.
Conclusions
Our analytical verification determines the ability of TST170 pipeline to detect 5% VAF with high confidence and CNVs in samples of tumor purity at 33% or more.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2507 - KEYLYNK-010: Phase 3 Study of Pembrolizumab (pembro) Plus Olaparib (OLA) vs Enzalutamide (ENZA) or Abiraterone (ABI) in ENZA- or ABI-Pretreated Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Had Progression on Chemotherapy (CTx)
Presenter: Evan Yu
Session: Poster Display session 3
Resources:
Abstract
2944 - PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastasic hormone-sensitive prostate cancer.
Presenter: Jose Arranz Arija
Session: Poster Display session 3
Resources:
Abstract
3535 - A phase 1 study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Ben Tran
Session: Poster Display session 3
Resources:
Abstract
4951 - ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer (EudraCT: 2018-002350-78, NCT03903835)
Presenter: Johan Lindberg
Session: Poster Display session 3
Resources:
Abstract
2892 - A phase 3 randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
2427 - The Extended/Phase II Study of Safety And Tolerability Of Proxalutamide (GT0918) In Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone (Abi) Or Enzalutamide (Enza)
Presenter: Nicholas Vogelzang
Session: Poster Display session 3
Resources:
Abstract
3224 - Addition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients with high risk N+M0 prostate cancer
Presenter: Marit Vermunt
Session: Poster Display session 3
Resources:
Abstract
3312 - A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy.
Presenter: Piet Dirix
Session: Poster Display session 3
Resources:
Abstract
2829 - Health-Related Quality of Life (HRQoL) and Updated Follow-Up From KEYNOTE-057: Phase 2 Study of Pembrolizumab (pembro) for Patients (pts) With High-Risk (HR) Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG)
Presenter: Ronald de Wit
Session: Poster Display session 3
Resources:
Abstract
2673 - Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract